<DOC>
	<DOCNO>NCT00766142</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving one drug ( combination chemotherapy ) together cetuximab may kill tumor cell . PURPOSE : This phase II trial study well chemotherapy give together cetuximab work treat patient undergo surgery remove peritoneal carcinomatosis colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Cetuximab Treating Patients Undergoing Surgery Peritoneal Carcinomatosis From Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy systemic chemotherapy cetuximab , term progression-free survival 3 year , patient completely resect peritoneal carcinomatosis colorectal origin . Secondary - Determine therapeutic strategy among patient fit receive chemotherapy . - Determine progression-free survival 5 year overall survival 3 5 year patient . - Determine overall tolerability ( mortality , morbidity ) regimen , include surgery , patient . OUTLINE : This multicenter study . Patients undergo complete resection peritoneal carcinomatosis . Beginning 4-8 week surgery , patient receive cetuximab IV 2.5 hour . Patients also receive FOLFOX chemotherapy comprise oxaliplatin IV leucovorin calcium IV 2 hour , fluorouracil IV continuously 46 hour . Treatment repeat every 2 week 12 course . After completion study therapy , patient follow every 4 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal adenocarcinoma meeting follow criterion : Exclusively peritoneal carcinomatosis ( metastasis ) Resectable disease Primary tumor may location another synchronous carcinomatosis Patients metastatic disease complete remission 1 year eligible regardless prior chemotherapy PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 12 week ANC ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Hemoglobin ≥ 10 g/dL Bilirubin ≤ 1.25 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Creatinine ≤ 1.25 time ULN Creatinine clearance ≥ 30 mL/min Not pregnant nursing Fertile patient must use effective contraception No allergy , hypersensitivity , contraindication leucovorin calcium , oxaliplatin , fluorouracil No noncancerous disease would preclude study therapy Good nutritional status No sensitive peripheral neuropathy functional impairment No hypoplasia bone marrow failure No clinically significant cardiovascular disease within past year ( e.g. , unstable angina myocardial infarction ) No cancer within past 5 year unless complete remission exception cervical carcinoma situ basal cell cancer No patient deprive liberty supervision No psychological , social , familial , geographical reason prohibit followup PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 1 year since prior adjuvant chemotherapy , include prior therapy oxaliplatin and/or cetuximab No prophylactic phenytoin ( Dihydan® , Dilantin® ) No prior yellow fever vaccine More 1 month since participation another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
</DOC>